Nautilus Biotechnology (NAUT) News Today $1.71 -0.06 (-3.39%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$1.71 0.00 (0.00%) As of 01/31/2025 05:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Short Interest Down 14.2% in DecemberNautilus Biotechnology, Inc. (NASDAQ:NAUT - Get Free Report) saw a large decline in short interest during the month of December. As of December 31st, there was short interest totalling 1,030,000 shares, a decline of 14.2% from the December 15th total of 1,200,000 shares. Currently, 1.8% of the shares of the stock are short sold. Based on an average daily trading volume, of 131,000 shares, the days-to-cover ratio is presently 7.9 days.January 16, 2025 | marketbeat.comJapan’s Kaneka buys Israeli medical device startup in $100 millon dealJanuary 9, 2025 | msn.comWith 32% ownership, Nautilus Biotechnology, Inc. (NASDAQ:NAUT) insiders have a lot riding on the company's futureDecember 9, 2024 | uk.finance.yahoo.comGoldman Sachs Downgrades Nautilus Biotechnology (NAUT)December 6, 2024 | msn.comNautilus Biotechnology (NASDAQ:NAUT) Stock Price Up 0.8% - Here's What HappenedNautilus Biotechnology (NASDAQ:NAUT) Trading 0.8% Higher - Should You Buy?November 23, 2024 | marketbeat.comNautilus Biotechnology, Inc. (NASDAQ:NAUT) Q3 2024 Earnings Call TranscriptOctober 31, 2024 | msn.comNautilus Biotechnology Faces ESG Challenges Amid Regulatory Pressure and Investor ScrutinyOctober 31, 2024 | markets.businessinsider.comNautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy for Radiology and Biomedical Imaging Research's Distinguished Investigator AwardOctober 31, 2024 | globenewswire.comNautilus Biotechnology Inc (NAUT) Q3 2024 Earnings Call Highlights: Strategic Advances and ...October 30, 2024 | finance.yahoo.comNautilus Biotechnology Reports Q3 2024 Financial ResultsOctober 30, 2024 | msn.comNautilus Biotechnology to Participate in the Inaugural Guggenheim Healthcare ConferenceOctober 30, 2024 | globenewswire.comNautilus Biotechnology Reports Third Quarter 2024 Financial ResultsOctober 30, 2024 | markets.businessinsider.comQ3 2024 Nautilus Biotechnology Inc Earnings CallOctober 30, 2024 | finance.yahoo.comTD Cowen Keeps Their Buy Rating on Nautilus Biotechnolgy (NAUT)October 30, 2024 | markets.businessinsider.comNautilus Biotechnology (NAUT) Scheduled to Post Quarterly Earnings on TuesdayNautilus Biotechnology (NASDAQ:NAUT) will be releasing earnings before the market opens on Tuesday, October 29, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=633846)October 22, 2024 | marketbeat.comWe Think Nautilus Biotechnology (NASDAQ:NAUT) Can Afford To Drive Business GrowthOctober 9, 2024 | finance.yahoo.comTech Moves: GE healthcare exec joins startup; Nautilus Biotech’s new CMO; WRF investor steps downSeptember 27, 2024 | msn.comNautilus Biotechnology, Inc. (NASDAQ:NAUT) VP Sells $134,978.97 in StockSeptember 26, 2024 | insidertrades.comNautilus Biotechnology, Inc. (NASDAQ:NAUT) VP Mary E. Godwin Sells 35,000 SharesSeptember 19, 2024 | insidertrades.comNautilus Biotechnology Insider Ups Holding During YearAugust 18, 2024 | finance.yahoo.comNautilus Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceAugust 14, 2024 | markets.businessinsider.comINOVIO Reports Q2 2024 Financial Results and Provides Business UpdateAugust 13, 2024 | msn.comNautilus Biotechnology (NASDAQ:NAUT) Announces Quarterly Earnings ResultsNautilus Biotechnology (NASDAQ:NAUT - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.02. During the same quarter last year, the firm posted ($0.13) earnings per share.July 31, 2024 | marketbeat.comNautilus Down on Releasing Q2 NumbersJuly 30, 2024 | msn.comNautilus Biotechnology Reports Second Quarter 2024 Financial ResultsJuly 30, 2024 | globenewswire.comNautilus Biotechnology Q2 2024 Earnings PreviewJuly 29, 2024 | msn.comNautilus Biotechnology (NASDAQ:NAUT) Trading Down 2.5%Nautilus Biotechnology (NASDAQ:NAUT) Shares Down 2.5%July 19, 2024 | marketbeat.comNautilus Biotechnology to Announce Second Quarter 2024 Financial Results on July 30, 2024July 9, 2024 | globenewswire.comNautilus Biotechnology (NASDAQ:NAUT) Research Coverage Started at GuggenheimGuggenheim initiated coverage on shares of Nautilus Biotechnology in a research note on Thursday. They set a "buy" rating and a $6.00 target price for the company.June 27, 2024 | marketbeat.comPerceptive Advisors LLC Buys 3,483,060 Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT)Perceptive Advisors LLC grew its holdings in Nautilus Biotechnology, Inc. (NASDAQ:NAUT - Free Report) by 38.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,594,211 shares of the company's stoJune 16, 2024 | marketbeat.comNautilus Biotechnology (NASDAQ:NAUT) Research Coverage Started at Jefferies Financial GroupJefferies Financial Group started coverage on shares of Nautilus Biotechnology in a research report on Monday. They set a "hold" rating and a $3.00 price target for the company.June 3, 2024 | marketbeat.comNautilus Biotechnology, Inc. (NASDAQ:NAUT) Q1 2024 Earnings Call TranscriptMay 1, 2024 | msn.comNautilus Biotechnology Inc (NAUT) Q1 2024 Earnings Call Transcript Highlights: A Detailed ...May 1, 2024 | finance.yahoo.comQ1 2024 Nautilus Biotechnology Inc Earnings CallMay 1, 2024 | finance.yahoo.comNAUT Stock Earnings: Nautilus Biotechnology Beats EPS for Q1 2024April 30, 2024 | investorplace.comNautilus Biotechnology Inc (NAUT) Q1 2024 Earnings: Narrower Loss Than ExpectedApril 30, 2024 | finance.yahoo.comNautilus Biotechnology GAAP EPS of -$0.15 beats by $0.01April 30, 2024 | msn.comNautilus Biotechnology Reports First Quarter 2024 Financial ResultsApril 30, 2024 | globenewswire.comJeff Bezos Earns So Much He Could Buy a Rolex Every Second — How Does He Make Money?April 25, 2024 | msn.comNautilus Biotechnology Inc Ordinary Shares NAUTApril 16, 2024 | morningstar.comNautilus Biotechnology to Announce First Quarter 2024 Financial Results on April 30, 2024April 11, 2024 | globenewswire.comNautilus Biotechnology, Inc. (NASDAQ:NAUT) CEO Sujal M. Patel Acquires 7,405 SharesMarch 17, 2024 | insidertrades.comStartup Mahakumbh Redefines India's Esports and Gaming IndustryMarch 12, 2024 | msn.comSujal M. Patel Purchases 12,044 Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) StockMarch 12, 2024 | insidertrades.comInsider Buying: Nautilus Biotechnology, Inc. (NASDAQ:NAUT) CEO Acquires $34,204.96 in StockNautilus Biotechnology, Inc. (NASDAQ:NAUT - Get Free Report) CEO Sujal M. Patel purchased 12,044 shares of the stock in a transaction dated Monday, March 11th. The shares were purchased at an average price of $2.84 per share, with a total value of $34,204.96. Following the completion of the acquisition, the chief executive officer now owns 10,064,488 shares of the company's stock, valued at $28,583,145.92. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.March 11, 2024 | marketbeat.comThis Nautilus Biotechnology Insider Increased Their Holding In The Last YearMarch 11, 2024 | finance.yahoo.comNautilus Biotechnology, Inc. (NAUT) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | seekingalpha.comNautilus Biotechnology, Inc. (NASDAQ:NAUT) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | finance.yahoo.comQ4 2023 Nautilus Biotechnology Inc Earnings CallFebruary 29, 2024 | finance.yahoo.comNautilus Biotechnology Inc (NAUT) Reports Fiscal Year 2023 Financial ResultsFebruary 28, 2024 | finance.yahoo.com Get Nautilus Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for NAUT and its competitors with MarketBeat's FREE daily newsletter. Email Address NAUT Media Mentions By Week NAUT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NAUT News Sentiment▼1.440.69▲Average Medical News Sentiment NAUT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NAUT Articles This Week▼21▲NAUT Articles Average Week Get Nautilus Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for NAUT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TRNS News Today CTKB News Today BNGO News Today SENS News Today LAB News Today EYPT News Today ALNT News Today QTRX News Today AEHR News Today QSI News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NAUT) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nautilus Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nautilus Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
